From: Is gene therapy a good therapeutic approach for HIV-positive patients?
Target cells | Vector | Transgene | Anti-HIV method | Results |
---|---|---|---|---|
CD8+ | Retrovirus | HyTk | Introduction of suicide gene | CTL response cleared modified cells [16]. |
CD4+ | Gold-particle-mediated | Rev M10 | Transdominant negative protein | Detected Rev M10 until 2 months post infusion, preferential survival [36]. |
CD4+ | Retrovirus | Rev M10 | Transdominant negative protein | Detected Rev M10 until 6 months post infusion, preferential survival [37]. |
CD4+ | Retrovirus | TdRev and/or anti-sense TAR | Transdominant negative proteins and anti-sense RNA | Anti-HIV genes consistently detected for >100 weeks in six of six patients. Preferential survival of transduced cells during a period of high viral load in one patient [47]. |
CD34+ | Retrovirus | TdRev | Transdominant negative protein | One patient died due to relapse to Hodgkin's disease. In second patient, detected vector in the progeny for >3 years, remission of leukemia and good viral load control achieved by administering HAART that cannot be attributed to gene therapy [38,39]. |
CD34+ | Retrovirus | huM10 | Transdominant negative protein | huM10 could be detected in peripheral blood mononuclear cells (PBMC) for 1–3 months and then dropped to at or below the limit of detection over a two year follow-up period. Preferential survival of transduced cells during a period of high viral load in one patient [40]. |
CD4+ | Retrovirus | CD4ζ | Chimeric receptor | Decrease of greater than 0.5 log mean in rectal tissue-associated HIV RNA for at least 14 days, detected CD4ζ in 1–3% of PBMCs at 8 weeks [42] |
CD4+ | Retrovirus | CD4ζ | Chimeric receptor | Good expression of CD4ζ for at least 24 weeks in all patients; no difference between control and study group [43]. |
CD4+ and CD8+ | Retrovirus | CD4ζ | Chimeric receptor | In 11 of 12 patients who received higher doses of modified CD8+ cells (109 or 1010), CD4ζ could be detected post-infusion for at least 15–40 weeks when they received additional infusions of modified cells. The group receiving IL-2 along with modified CD8+ cells showed a higher persistence of CD4ζ as compared to the group receiving no IL-2. In patients who received modified CD8+ and CD4+ cells, the cells were detected in the peripheral blood for at least 1 year post-infusion [41]. |
CD34+ | Retrovirus | (RRE) decoy | RNA decoy | RRE-decoy-containing leukocytes could be isolated from peripheral blood even 1 year post-infusion but the numbers were extremely low [44]. |
CD4+ | Retrovirus | RRz2 | Ribozyme | Over a 4 year period, PBMCs containing both RRz2 and LNL6 were consistently detected [46]. |
CD34+ | Retrovirus | tat/vpr ribozyme | Ribozyme | Vector was detected in naïve T cells for >3 years; no correlation between changes in viremia or CD4+ T cell counts with vector expression or its detection in any cell type [45]. |